Copyright
©The Author(s) 2020.
World J Gastroenterol. Feb 14, 2020; 26(6): 645-656
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.645
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.645
Table 1 Demographic and clinical characteristics, laboratory tests, and severity scores of patients on admission
Characteristic | All patients (n = 1281) | Without BI (n = 921) | With BI (n = 360) | P value |
Median age (IQR) -yr | 51 (42-57) | 52 (43-57) | 50 (42-57) | 0.16 |
Male sex (%) | 1012 (79) | 726 (78.8) | 286 (79.4) | 0.88 |
Concomitant etiology of cirrhosis (%) | ||||
Alcohol | 142 (11.1) | 102 (11.1) | 40 (11.1) | 1.00 |
Others | 48 (3.7) | 36 (3.9) | 12 (3.3) | 0.74 |
HBeAg positive HBV (%)1 | 421/1122 (37.5) | 298/794 (37.5) | 123/328 (37.5) | 1.00 |
Experience of anti-HBV treatment (%)1 | 284/1176 (24.2) | 183/851 (21.5) | 101/325 (31.1) | < 0.001 |
Decompensations (%)2 | ||||
Ascites | 1099 (85.8) | 773 (83.9) | 326 (90.6) | < 0.01 |
Jaundice | 534 (41.7) | 297 (32.2) | 237 (65.8) | < 0.001 |
Gastrointestinal variceal bleeding | 336 (26.2) | 280 (30.4) | 56 (15.6) | < 0.001 |
Hepatic encephalopathy | 190 (14.8) | 82 (8.9) | 108 (30) | < 0.001 |
ACLF at admission (%) | 284 (22.2) | 130 (14.1) | 154 (42.8) | < 0.001 |
Median value for laboratory tests (IQR) | ||||
Log10 HBV DNA (copies/mL)3 | 4.7 (3.1-6.1) | 4.8 (3-6.2) | 4.6 (3.1-5.7) | 0.33 |
Hemoglobin (g/L) | 103 (83-121) | 102 (82-119) | 107 (87-127) | < 0.001 |
White cell count: × 109 cells/L | 4.7 (2.9-7.5) | 4.2 (2.7-6.1) | 6.9 (4.3-10.9) | < 0.001 |
Platelet count: × 109 cells/L | 63 (40-102) | 60 (40-96) | 70 (42-117.5) | < 0.01 |
International normalized ratio | 1.6 (1.3-2) | 1.4 (1.3-1.9) | 1.8 (1.5-2.6) | < 0.001 |
Serum sodium (mmol/L) | 136 (131.2-139) | 136 (132.3-139.3) | 134 (129-137) | < 0.001 |
Serum creatinine (mg/dL) | 0.8 (0.7-1) | 0.8 (0.7-1) | 0.8 (0.6-1.1) | 0.20 |
Aspartate aminotransferase (IU/L) | 67 (42-124) | 60 (40-107) | 97 (56.5-192) | < 0.001 |
Alanine aminotransferase (IU/L) | 47 (30-97) | 42 (29-80) | 67 (37-185.8) | < 0.001 |
Total bilirubin (mg/dL) | 3.4 (1.5-15.5) | 2.6 (1.4-8) | 10.9 (3-27.4) | < 0.001 |
Serum albumin (g/dL) | 2.8 (2.5-3.2) | 2.9 (2.5-3.3) | 2.8 (2.4-3.1) | < 0.001 |
Median value for severity scores (IQR) | ||||
Child-Pugh | 11 (9-12) | 10 (8-12) | 12 (10-13) | < 0.001 |
MELD | 16.8 (11.8-25.5) | 14.8 (11.1-22.3) | 24.4 (17.1-30.2) | < 0.001 |
Table 2 Characteristics of bacterial infection according to in-hospital outcome
Characteristic | All patient (n = 1281) | Survivors (n = 1101) | Non-survivors (n = 180) | P value1 |
Bacterial infection | 360 (28.1) | 247 (22.4) | 113 (62.8) | < 0.001 |
Source of acquisition | ||||
Community-acquired | 76 (5.9) | 58 (5.3) | 18 (10) | 0.02 |
Healthcare-associated | 136 (10.6) | 89 (8.1) | 47 (26.1) | < 0.001 |
Nosocomial infection | 162 (12.6) | 107 (9.7) | 55 (30.6) | < 0.001 |
Single site | ||||
Pneumonia | 126 (9.8) | 75 (6.8) | 51 (28.3) | < 0.001 |
Spontaneous bacterial peritonitis | 69 (5.4) | 47 (4.3) | 22 (12.2) | < 0.001 |
Urinary tract infection | 29 (2.3) | 26 (2.4) | 3 (1.7) | 0.79 |
Spontaneous bacteremia | 16 (1.3) | 14 (1.3) | 2 (1.1) | 1.00 |
Skin or soft tissue infection | 9 (0.7) | 7 (0.6) | 2 (1.1) | 0.37 |
Others2 | 17 (1.3) | 15 (1.4) | 2 (1.1) | 1.00 |
Multi sites | 34 (2.7) | 20 (1.8) | 14 (7.8) | < 0.001 |
Unknown site3 | 60 (4.7) | 43 (3.9) | 17 (9.4) | < 0.01 |
Table 3 Univariate competing risk analysis of risk factors for in-hospital survival
Parameters | Without ACLF at admission | ACLF at admission | ||
sHR (95%CI) | P value | sHR (95%CI) | P value | |
Age (yr) | 1.01 (0.99-1.03) | 0.22 | 1.02 (1.00-1.03) | 0.03 |
Male sex (%) | 1.37 (0.74-2.54) | 0.32 | 0.97 (0.59-1.60) | 0.91 |
Ascites (%) | 2.88 (1.05-7.93) | 0.04 | 1.11 (0.57-2.17) | 0.76 |
V Gastrointestinal variceal bleeding (%) | 0.65 (0.37-1.14) | 0.13 | 0.64 (0.22-1.81) | 0.40 |
Hepatic encephalopathy (%) | 0.96 (0.36-2.57) | 0.93 | 1.90 (1.28-2.83) | < 0.01 |
Jaundice (%) | 5.10 (3.10-8.39) | < 0.001 | 2.45 (1.20-5.03) | < 0.001 |
Bacterial infection (%) | 4.94 (3.08-7.94) | < 0.001 | 2.34 (1.52-3.59) | < 0.001 |
Pneumonia (%) | 4.79 (2.86-8.03) | < 0.001 | 2.06 (1.39-3.05) | < 0.001 |
Spontaneous bacterial peritonitis (%) | 4.05 (2.19-7.48) | < 0.001 | 1.49 (0.88-2.53) | 0.13 |
Urinary tract infection (%) | 0.94 (0.23-3.81) | 0.93 | 1.34 (0.67-2.68) | 0.41 |
HBeAg positive HBV (%) | 0.92 (0.56-1.54) | 0.76 | 1.08 (0.78-1.63) | 0.70 |
Log10 HBV DNA (copies/mL) | 1.04 (0.90-1.21) | 0.57 | 1.10 (0.96-1.25) | 0.18 |
White cell count (× 109 cells/L) | 1.11 (1.07-1.16) | < 0.001 | 1.04 (1.01-1.06) | 0.02 |
Total bilirubin (mg/dL) | 1.05 (1.03-1.06) | < 0.001 | 1.02 (1.01-1.03) | < 0.01 |
Serum creatinine (mg/dL) | 1.87 (0.59-5.93) | 0.29 | 1.05 (0.96-1.15) | 0.25 |
International normalized ratio | 1.97 (1.56-2.49) | < 0.001 | 1.09 (0.93-1.29) | 0.31 |
Serum albumin (g/dL) | 0.41 (0.27-0.64) | < 0.001 | 0.63 (0.45-0.88) | < 0.01 |
Serum sodium (mmol/L) | 0.91 (0.88-0.93) | < 0.001 | 0.98 (0.95-1.01) | 0.14 |
Table 4 Multivariate competing risk analysis of risk factors for in-hospital survival
Parameters | Estimate | Standard error | sHR (95%CI) | P value |
Without ACLF at admission | ||||
Bacterial infection | 1.1872 | 0.2708 | 3.28 (1.93-5.57) | < 0.001 |
Total bilirubin at admission | 0.0292 | 0.0104 | 1.03 (1.01-1.05) | < 0.01 |
Albumin at admission | -0.7695 | 0.2357 | 0.46 (0.29-0.74) | < 0.01 |
Sodium at admission | -0.0738 | 0.0178 | 0.93 (0.9-0.96) | < 0.001 |
ACLF at admission | ||||
Pneumonia | 0.6250 | 0.2106 | 1.87 (1.24-2.82) | < 0.01 |
Hepatic encephalopathy | 0.5453 | 0.2068 | 1.73 (1.15-2.59) | < 0.01 |
Total bilirubin at admission | 0.0277 | 0.0081 | 1.03 (1.01-1.04) | < 0.001 |
Albumin at admission | -0.7110 | 0.1945 | 0.49 (0.34-0.72) | < 0.001 |
- Citation: Cao ZJ, Liu YH, Zhu CW, Yin S, Wang WJ, Tang WL, Zhao GD, Xu YM, Chen L, Zhou TH, Cai MH, Wang H, Cai W, Bao SS, Li H, Xie Q. Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: A retrospective cohort study. World J Gastroenterol 2020; 26(6): 645-656
- URL: https://www.wjgnet.com/1007-9327/full/v26/i6/645.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i6.645